Akros SCHK HK-Korea Low Volatility Factor Index

Samsung Biologics expects to publish the formal PolyPeptide tender-offer prospectus by the end of August 2026.

KRAFTON is scheduled to showcase five new titles, including an unannounced PUBG STUDIOS game, at Gamescom 2026 in Cologne beginning August 26.

DB Insurance is scheduled by two independent earnings calendars to report its Q2 2026 results on 19 August 2026.

KT is expected to report its second-quarter 2026 results on August 18, 2026, although the company had not confirmed the date as of July 24.

Yuhan Corp is due to file its H1 2026 interim report by August 14, 2026, creating the next formal earnings and Lazcluze-royalty disclosure catalyst.

LG Uplus is estimated to report its second-quarter 2026 results on August 6, 2026.

KT&G will present its 2026 second-quarter operating results and hold an investor Q&A by conference call and live webcast on 6 August 2026 at 16:00.

KRAFTON’s PUBG Global Series Circuit 3 is scheduled to run in Shanghai from August 5 through August 23, comprising PGS 7–9 with a total $500,000 prize pool.

KRAFTON is scheduled to present its 2026 second-quarter and first-half management results and hold a Q&A webcast on July 29 at 16:00 KST.

Samsung Card is scheduled by independent earnings calendars to release its Q2 2026 results on July 28, 2026.

BNK Financial Group scheduled its Q2 2026 results presentation for 15:30 KST on July 28, followed by domestic institutional-investor meetings from July 30 to August 4 and on August 12.

Industrial Bank of Korea scheduled release of its results for the six months ended June 30, 2026 for July 27, 2026.

KT said it continues to review options to strengthen AX competitiveness, including the reported merger with subsidiary KT Cloud, but that no specific decision has been made.

Celltrion submitted updated global Phase 3 trial applications for CT-P13 SC (Zymfentra) in rheumatoid arthritis to the FDA, EMA and South Korea's MFDS.

Celltrion submitted a European marketing-authorization application for CT-P55, its secukinumab biosimilar referencing Cosentyx, across the reference product's EU indications.

Hana Financial Group announced Corporate Value Enhancement Plan 2.0, raising its ROE target to 12%, setting a shareholder-return target above 50%, and targeting CET1 above 13%.

Hana Financial Group reported record first-half 2026 controlling net income of KRW 2.4029 trillion, including KRW 1.1928 trillion in the second quarter.

BNK Financial Group completed the KRW 60 billion buyback trust with 3,487,282 shares acquired for KRW 59.99999 billion and set their cancellation for August 14, 2026.

Tongyang Life shareholders approved, and Woori Financial's board approved, the comprehensive share exchange that will make Tongyang Life a wholly owned subsidiary.

Woori Financial reported first-half 2026 attributable net income of KRW 1.609 trillion, up 3.7% year on year, and approved expanded shareholder returns.

Shinhan Financial Group released 2Q 2026 attributable net income of KRW 1.8201 trillion, up 17.5% year over year.

Shinhan Financial Group authorized a KRW 700 billion market repurchase of an estimated 6,698,564 common shares from July 31 to October 22, 2026, to be cancelled after acquisition.

KB Financial Group reported first-half 2026 attributable net profit of KRW 3.885 trillion, up 13.1% year over year.

KB Financial Group authorized a KRW 700 billion treasury-share buyback trust, with all shares acquired under the program to be cancelled.

Samsung Biologics filed its preliminary Q2 2026 results on DART, reporting revenue of KRW 1.3209 trillion and operating profit of KRW 586.4 billion, up 30.2% and 22.9% year over year, respectively.

KRAFTON announced a strategic investment in game-commerce infrastructure provider Neon Commerce to develop proprietary payment capabilities and expand direct engagement with global users.

LG Uplus and Ericsson announced a strategic partnership to develop network-based voice AI and pursue global commercialization.

LG Uplus and LS ELECTRIC signed an MOU to jointly develop and validate 800V DC power infrastructure for AI data centers.

Samsung Biologics announced an all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share, implying equity value of about CHF 1.46 billion (KRW 2.706 trillion).